Archives
- 2018-07
- 2019-04
- 2019-05
- 2019-06
- 2019-07
- 2019-08
- 2019-09
- 2019-10
- 2019-11
- 2019-12
- 2020-01
- 2020-02
- 2020-03
- 2020-04
- 2020-05
- 2020-06
- 2020-07
- 2020-08
- 2020-09
- 2020-10
- 2020-11
- 2020-12
- 2021-01
- 2021-02
- 2021-03
- 2021-04
- 2021-05
- 2021-06
- 2021-07
- 2021-08
- 2021-09
- 2021-10
- 2021-11
- 2021-12
- 2022-01
- 2022-02
- 2022-03
- 2022-04
- 2022-05
- 2022-06
- 2022-07
- 2022-08
- 2022-09
- 2022-10
- 2022-11
- 2022-12
- 2023-01
- 2023-02
- 2023-03
- 2023-04
- 2023-05
- 2023-06
- 2023-08
- 2023-09
- 2023-10
- 2023-11
- 2023-12
- 2024-01
- 2024-02
- 2024-03
- 2024-04
- 2024-05
- 2024-06
- 2024-07
- 2024-08
- 2024-09
- 2024-10
- 2024-11
-
br TRIM TIF A RNF TRIM contains
2019-07-09
TRIM24 (TIF1A, RNF82) TRIM24 contains a RING-both B-boxes-coiled coil conserved structure at the N-terminus with bromo and PHD domains prior to C-terminal end (Fig. 3). This transcriptional intermediary factor is well studied in the context of transcriptional activation of nuclear receptor via ac
-
The E enzyme is the apex for downstream enzymatic
2019-07-08
The E1 enzyme is the apex for downstream enzymatic cascades and signaling pathways mediated by Ub and Ub-like proteins (Ubls) (Pickart, 2001). Studying characteristics of E1 and its catalytic functions may throw light to the role of ubiquitination in cell development. All known eukaryotic E1 are mon
-
The compounds were ranked based on the Glide XP Score
2019-07-08
The compounds were ranked based on the Glide XP Score, as shown in . All 15 compounds were subject to a radiometric assay previously used in our lab to evaluate their ability to inhibit DHFR steady-state activity in recombinant TS-DHFR (A). Compound demonstrated greater than 50% inhibition of DHFR
-
In conclusion we developed a new CysLT
2019-07-08
In conclusion, we developed a new CysLT1 and CysLT2 receptors-mediated anaphylaxis guinea pig model that can be useful for screening both CysLT2 receptor and CysLT1/2 receptor antagonists. In addition, we have shown that the dual CysLT1/2 receptor antagonist ONO-6950 can exert protective effect agai
-
The full length human CPG protein is
2019-07-08
The full-length human CPG2 protein is expressed in CNS tissue with the highest expression in the neocortex, hippocampus and striatum, consistent with mRNA localization patterns of the rat Cpg2 homolog (Cottrell et al., 2004). In the rat, the CPG2 protein localizes primarily to the postsynaptic endoc
-
It remains unclear how LINE RNA Nucleolin Kap are
2019-07-08
It remains unclear how LINE1 RNA-Nucleolin-Kap1 are targeted to the Dux cluster. LINE1-Nucleolin-Kap1 may have other interacting partners with DNA binding specificity. For example, YY1 has been implicated in targeting a repressive complex containing Nucleolin to the human DUX4 cluster (Gabellini et
-
br Experiments br Numerical simulations br Discussion br Con
2019-07-08
Experiments Numerical simulations Discussion Conclusions By large-caliber PELE with various d/D against RHA plate at low velocity of 415 m s−1, impact experiments against 30 mm RHA target were carried out. Numerical simulations were also conducted to monitor progress of PELE expansion an
-
br Materials and methods br Results
2019-07-08
Materials and methods Results Discussion It has been demonstrated that up-regulation of EPHB4 impaired trophoblast migration and invasion during placentation, which may contribute to the pathogenesis of preeclampsia [11], [24]. However, the upstream regulating mechanism of EPHB4 expression
-
α-Bungarotoxin Given the fact that most criticism
2019-07-08
Given the fact that most criticism on genetic association studies is the lack of replicability (Hirschhorn, Lohmueller, Byrne, & Hirschhorn, 2002), the aim of the present study is to investigate the influence of the DBH polymorphism rs1611115 (C-970T) on RD in two independent samples of healthy part
-
RLS is a genetically complex disorder in which genetic and
2019-07-08
RLS is a genetically complex disorder in which genetic and environmental factors contribute to the phenotype (Trenkwalder, Allen, Högl, Paulus, & Winkelmann, 2016). This disease is highly familial and six genetic variants with single nucleotide polymorphisms have been identified by genome-wide assoc
-
br Acknowledgments Studies in the Tomkinson laboratory
2019-07-08
Acknowledgments Studies in the Tomkinson laboratory on DNA ligase III are supported by research grants from the National Institutes of Health (P01 CA92584 and ES12512 to AET), a grant from the V Foundation and the University of New Mexico Cancer Center. Introduction Ionizing radiation (IR) as
-
Tempol what The efficacy of A in the ob ob
2019-07-08
The efficacy of A-922500 in the ob/ob mouse model is of particular interest for two reasons. One of the most striking features of the DGAT-1 deficient mouse phenotype is the resistance to diet-induced obesity (Smith et al., 2000). However, Tempol what of DGAT-1 in leptin deficient ob/ob mice failed
-
Several highly potent CysLT receptor antagonists with large
2019-07-08
Several highly potent CysLT1 receptor antagonists with large structural Rifaximin have been developed. Beyond antagonists with structures analogous to cysteinyl leukotrienes, other subclasses comprise: (a) hydroxyacetophenones, (b) indoles and indazoles, (c) quinolines, benzothiazoles, and thiazole
-
Regarding eicosanoid production iPLA VIA appears in general
2019-07-05
Regarding eicosanoid production, iPLA2-VIA appears, in general terms, not to play a major role in mediating this response in innate immunity and inflammation, as evidenced by the large number of studies highlighting the lack of effect of selective inhibition of the enzyme in stimulus-induced AA rele
-
ELUXA HM EMSI is an ongoing pivotal Phase II global
2019-07-05
ELUXA 1 (HM-EMSI-202) is an ongoing pivotal Phase II global clinical trial, designed to further investigate the efficacy and safety of Olmutinib in patients T790M-positive NSCLC with acquired resistance after first-line EGFR TKIs. Primary endpoint is ORR according to RECIST 1.1, while secondary endp
14664 records 937/978 page Previous Next First page 上5页 936937938939940 下5页 Last page